• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[生物制药的药理学基础]

[Basics of the pharmacology of biopharmaceuticals].

作者信息

Wohlrab Johannes

机构信息

Universitätsklinik und Poliklinik für Dermatologie und Venerologie, Martin-Luther-Universität Halle-Wittenberg, Ernst-Grube-Str. 40, 06097, Halle (Saale), Deutschland.

Institut für angewandte Dermatopharmazie, Martin-Luther-Universität Halle-Wittenberg, Halle (Saale), Deutschland.

出版信息

Hautarzt. 2019 Dec;70(12):926-933. doi: 10.1007/s00105-019-04502-4.

DOI:10.1007/s00105-019-04502-4
PMID:31712972
Abstract

Biopharmaceuticals are pharmaceutical drug products or preparations of pharmaceutical drugs that are of biological origin or are manufactured from biological material. The spectrum of biological drugs is extensive and includes substances isolated from biological material, recombinant RNA molecules, proteins as well as full antibodies, antibody fragments or antibody-drug conjugates. The special features of the molecular properties and functions of biopharmaceuticals require a highly complex, variable structure. Due to the specificity of intended pharmacodynamic effects on a complex biological regulatory system, particularities regarding undesired effects, pharmacokinetics, and safety have to be considered both regulatory and clinical.

摘要

生物制药是指源于生物或由生物材料制成的药物产品或药物制剂。生物药物的范围广泛,包括从生物材料中分离出的物质、重组RNA分子、蛋白质以及完整抗体、抗体片段或抗体药物偶联物。生物制药分子特性和功能的特殊之处需要高度复杂、可变的结构。由于对复杂生物调节系统预期的药效学作用具有特异性,在监管和临床方面都必须考虑不良作用、药代动力学和安全性等方面的特殊性。

相似文献

1
[Basics of the pharmacology of biopharmaceuticals].[生物制药的药理学基础]
Hautarzt. 2019 Dec;70(12):926-933. doi: 10.1007/s00105-019-04502-4.
2
[Variants of biotechnological drugs in dermatology : Status quo and future].[皮肤科生物技术药物的变体:现状与未来]
Dermatologie (Heidelb). 2024 Oct;75(10):775-780. doi: 10.1007/s00105-024-05403-x. Epub 2024 Aug 22.
3
Emerging trends in pulmonary delivery of biopharmaceuticals.生物制药肺部给药的新趋势。
Drug Discov Today. 2022 May;27(5):1474-1482. doi: 10.1016/j.drudis.2022.02.003. Epub 2022 Feb 7.
4
Nonclinical development of biopharmaceuticals.生物制药的非临床开发。
Drug Discov Today. 2009 Dec;14(23-24):1112-22. doi: 10.1016/j.drudis.2009.09.013. Epub 2009 Oct 21.
5
[Biologics - nomenclature and classification].[生物制品 - 命名与分类]
Ther Umsch. 2011 Nov;68(11):593-601. doi: 10.1024/0040-5930/a000219.
6
Nanomedicines for delivery of therapeutic proteins and biopharmaceuticals.用于递送治疗性蛋白质和生物制药的纳米药物。
Ther Deliv. 2010 Aug;1(2):231-5. doi: 10.4155/tde.10.39.
7
The Pharmaceutical Industry in 2018. An Analysis of FDA Drug Approvals from the Perspective of Molecules.2018 年制药行业。从分子角度分析 FDA 药物批准情况。
Molecules. 2019 Feb 23;24(4):809. doi: 10.3390/molecules24040809.
8
Antibody Fragments as Potential Biopharmaceuticals for Cancer Therapy: Success and Limitations.抗体片段作为癌症治疗的潜在生物制药:成功与局限。
Curr Med Chem. 2019;26(3):396-426. doi: 10.2174/0929867324666170817152554.
9
N-glycans of complex glycosylated biopharmaceuticals and their impact on protein clearance.复杂糖基化生物制药的 N-聚糖及其对蛋白质清除的影响。
Eur J Pharm Biopharm. 2019 Jun;139:123-131. doi: 10.1016/j.ejpb.2019.03.018. Epub 2019 Mar 21.
10
Drug-binding cavities in long-lived biologics: cause for concern but also potential benefit.长效生物制品中的药物结合腔:令人担忧但也有潜在益处。
J Clin Pharmacol. 2008 Oct;48(10):1208-11. doi: 10.1177/0091270008323259.

本文引用的文献

1
Design and Production of Bispecific Antibodies.双特异性抗体的设计与生产。
Antibodies (Basel). 2019 Aug 2;8(3):43. doi: 10.3390/antib8030043.
2
Immunogenicity of Innovative and Biosimilar Monoclonal Antibodies.创新型和生物类似单克隆抗体的免疫原性
Antibodies (Basel). 2019 Mar 5;8(1):21. doi: 10.3390/antib8010021.
3
Modelling of the Time-Varying Pharmacokinetics of Therapeutic Monoclonal Antibodies: A Literature Review.治疗性单克隆抗体时变药代动力学建模:文献综述。
Clin Pharmacokinet. 2020 Jan;59(1):37-49. doi: 10.1007/s40262-019-00816-7.
4
Cytokine release syndrome and neurologic toxicities associated with chimeric antigen receptor T-cell therapy: A comprehensive review of emerging grading models.嵌合抗原受体T细胞疗法相关的细胞因子释放综合征和神经毒性:新兴分级模型的全面综述
Hematol Oncol Stem Cell Ther. 2020 Mar;13(1):1-6. doi: 10.1016/j.hemonc.2019.05.005. Epub 2019 Jun 10.
5
Trifunctional antibodies unleash NK cells.
Nat Rev Cancer. 2019 Jul;19(7):369. doi: 10.1038/s41568-019-0166-0.
6
Biologics for chronic inflammatory skin diseases: an update for the clinician.用于慢性炎症性皮肤病的生物制剂:临床医生的最新进展。
J Dermatolog Treat. 2020 Mar;31(2):108-130. doi: 10.1080/09546634.2019.1589643. Epub 2019 Mar 25.
7
Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation.微小RNA生物合成、作用机制及循环概述
Front Endocrinol (Lausanne). 2018 Aug 3;9:402. doi: 10.3389/fendo.2018.00402. eCollection 2018.
8
Trifunctional metasurfaces: concept and characterizations.三功能超表面:概念与特性
Opt Express. 2018 Jun 25;26(13):17447-17457. doi: 10.1364/OE.26.017447.
9
Bispecific antibodies in cancer immunotherapy.癌症免疫治疗中的双特异性抗体。
Ther Adv Vaccines Immunother. 2018 Feb;6(1):3-17. doi: 10.1177/2515135518763280. Epub 2018 Mar 28.
10
Systematic review of anti-drug antibodies of IL-17 inhibitors for psoriasis.银屑病IL-17抑制剂抗药抗体的系统评价
J Dermatolog Treat. 2019 Mar;30(2):110-116. doi: 10.1080/09546634.2018.1473552. Epub 2018 May 18.